- BioDelivery Sciences (BDSI) +27.2% AH after the company and Endo Health Solutions (ENDP) announce a late-stage clinical trial for their new chronic pain medication showed significantly improved pain relief.
- The Phase III trial successfully met its primary efficacy endpoint in demonstrating that BEMA buprenorphine resulted in significantly improved chronic pain relief compared to a placebo.
- ENDP +2.4% AH.
BioDelivery +27% AH on positive clinical trial results for pain relief drug
Jan 23 2014, 19:00 ET